Megan Garlapow, PhD

Megan Garlapow, PhD, is the principal and owner of The Line Medical Communications, LLC, where she brings extensive experience in medical communications across diverse therapeutic areas. Dr Garlapow earned her BA in biology from the University of Chicago and her PhD in genetics from North Carolina State University. With a strong background in biomedical science and genetics, Dr Garlapow has held key roles in medical education and clinical genetics and genomics, where she honed her skills in developing strategic proposals, securing funding, delivering high-quality educational content, and composing engaging medical journalism pieces.

All articles by Megan Garlapow, PhD

Gut bacteria linked to heart and digestive symptoms in ATTR-CM

Understanding how bacteria interact with heart and digestive health could lead to more personalized treatments for patients with ATTR.
Early diagnosis and targeted treatment helped patient with ATTR-CM

A patient with transthyretin amyloid cardiomyopathy (ATTR-CM) benefited from early diagnosis and treatment with an oral transthyretin stabilizer, according to a case report published recently in Cureus. The 67-year-old man experienced lessening symptoms of heart failure after starting on the stabilizer. Despite worsening shortness of breath, swelling in his legs and reduced exercise tolerance, he […]
Growing awareness and better diagnostics are changing ATTR-CM’s rare disease status

ATTR-CM is being diagnosed more frequently because of improved awareness and diagnostic tools, making it more common than previously thought.
European Commission approves acoramidis to treat ATTR-CM in the EU

The European Commission approved acoramidis to treat adults with wild-type or variant ATTR-CM in the European Union.
Global review of transthyretin amyloidosis shows wide disparities among regions

Despite treatment advancements, ATTR remains poorly understood, with significant variations in prevalence and survival rates across regions.
New therapies offer hope for patients with ATTR-CM

Emerging therapies — including TTR stabilizers, silencers and depleters — offer new hope for managing ATTR-CM.
Advances have improved ATTR-CM detection and treatment

Advances in radionuclide imaging and emerging therapies have improved diagnosis and management of ATTR-CM.
Advanced therapies improve the outlook for patients with ATTR-CM

Treatment advances such as RNA silencing and gene-editing technologies offer hope to improve outcomes for patients with ATTR-CM.
New technology could advance genetic therapies to treat ATTR-CM

Minimal versatile genetic perturbation technology showed promise in addressing genetic diseases such as ATTR-CM.
Coronary disease does not worsen outcomes in patients with cardiac amyloidosis

Older patients faced a higher prevalence of coexisting cardiac amyloidosis, including ATTR-CM, and coronary artery disease.

Megan Garlapow, PhD

All articles by Megan Garlapow, PhD

The ATTR-CM Journey